Lys-Pro-Val — Alpha-MSH C-Terminal Tripeptide
A tripeptide derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (α-MSH), KPV retains the parent molecule's potent anti-inflammatory properties without its melanogenic effects. It directly targets NF-κB inflammatory signalling, PepT1-mediated gut uptake, and MCR1 receptor activation — making it uniquely effective for gut inflammation. A core component of the GLOW/KLOW blend and increasingly studied for IBD, leaky gut, and skin inflammation.
01 — Research Summary
KPV has a solid preclinical research base focused primarily on inflammatory bowel disease and gut mucosal healing, with growing interest in skin inflammation and wound healing applications.
Significant reduction in colitis severity and inflammatory markers. Multiple IBD models have consistently shown KPV reduces colon inflammation, preserves mucosal integrity, and reduces pro-inflammatory cytokine expression (TNF-α, IL-6, IL-1β) — providing strong mechanistic grounding for its gut application.
Oral bioavailability confirmed via PepT1 transporter. Research confirmed KPV is actively transported across the gut epithelium via the PepT1 peptide transporter — explaining why oral administration can achieve meaningful gut tissue concentrations, unlike most peptides that are degraded before absorption.
Reduced inflammatory marker expression in keratinocytes. Topical KPV application significantly reduced inflammatory marker expression in UV-exposed and chemically irritated skin cells, supporting its use in inflammatory skin conditions and positioning it as a research compound for dermatological applications.
Accelerated wound closure and reduced scar formation. Preclinical wound healing studies showed KPV accelerated epithelial closure and reduced inflammatory infiltration at wound sites — consistent with its NF-κB inhibition mechanism and complementary to GHK-Cu's wound healing effects.
02 — Mechanism of Action
KPV operates through two primary mechanisms — direct NF-κB pathway inhibition and melanocortin receptor activation — both of which converge on reduced inflammatory signalling.
KPV activates melanocortin 1 receptors (MCR1), the same receptor targeted by the parent molecule α-MSH. MCR1 activation drives downstream anti-inflammatory signalling — suppressing pro-inflammatory cytokine production and modulating immune cell activity without the melanogenic effects of full α-MSH.
KPV directly inhibits nuclear factor kappa B (NF-κB) — one of the master regulators of inflammatory gene expression. By blocking NF-κB activation, KPV reduces transcription of TNF-α, IL-6, IL-1β, and other pro-inflammatory cytokines simultaneously.
In the gut, KPV is actively absorbed via the PepT1 oligopeptide transporter expressed in intestinal epithelial cells. This transporter-mediated uptake bypasses the normal enzymatic degradation that prevents most peptides from reaching gut tissue intact when taken orally.
Beyond suppressing inflammation, KPV supports restoration of tight junction proteins that maintain gut barrier integrity — addressing leaky gut at the structural level alongside the inflammatory modulation.
KPV is one of the four components of the GLOW/KLOW blend alongside GHK-Cu, BPC-157, and TB-500. Its role in the blend is primarily gut protection and anti-inflammatory support — moderating the systemic inflammatory response while the other three compounds drive tissue repair and regeneration. This makes the KLOW blend (which includes KPV) more suited to gut-focused protocols than GLOW.
03 — Dosing Protocols
KPV can be administered orally, subcutaneously, or topically depending on the target application. Oral dosing is viable due to PepT1-mediated transport — unusual among peptides.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Oral — gut health | 500–1,500 mcg | Daily | 8–12 weeks | Oral capsule or liquid. PepT1 transport enables gut tissue delivery. Most used for IBD / leaky gut protocols. |
| Subcutaneous — systemic | 200–500 mcg | Daily | 8–12 weeks | Subcutaneous injection for systemic anti-inflammatory effect. More predictable bioavailability than oral. |
| Topical — skin inflammation | 0.1–0.5% solution | 1–2x daily | As needed | Applied to affected skin areas. Research supports topical efficacy for inflammatory skin conditions. |
| Combined with BPC-157 (oral) | 500 mcg KPV + 250 mcg BPC-157 | Daily | 8–12 weeks | Gut healing stack — complementary mechanisms for IBD and leaky gut protocols. |
KPV has a favourable safety profile in preclinical research with no significant adverse effects documented. Mild GI discomfort reported by some oral users. Not FDA-approved for any indication. Human clinical trial data is limited — the evidence base is predominantly preclinical.
04 — Community Experiences
KPV is discussed heavily in gut health communities — r/HealingIBD, r/SIBO, r/Peptides — and is increasingly present in biohacking discussions around leaky gut and inflammatory conditions. Its inclusion in the GLOW/KLOW blend has driven significant mainstream awareness. Key community themes: the oral route is valued highly by users who want gut-targeted effects without injections; stacking with BPC-157 is almost universal in gut protocols; and skin application is an emerging use case.
These are user-reported experiences from public forums. Not endorsed by Whats That Peptide and should not be interpreted as clinical evidence. Individual results vary. Always consult a healthcare professional.
"Crohn's flares significantly reduced. I've been on KPV + BPC-157 oral for 12 weeks. CRP dropped. Gut motility improved. I was skeptical of the oral route for a peptide but the PepT1 mechanism seems to be real..."
"Different mechanisms, better together. BPC-157 drives the repair and angiogenesis. KPV quiets the inflammatory environment so repair can happen. Running both makes more sense than choosing one..."
"Started using KPV solution topically for rosacea after reading the skin inflammation research. Significant reduction in redness after 6 weeks. Not a cure but the best results I've had from anything topical..."
"The oral bioavailability question is real. PepT1 transport is confirmed but the systemic concentration from oral dosing is lower than injection. For gut-specific effects, oral makes sense. For systemic anti-inflammatory effects, injectable is more reliable..."